Identification and selection of immunodominant B and T cell epitopes for dengue multi-epitope-based vaccine.
B cell
CD4+ T cell
CD8+ T cell
Dengue
Epitope
Vaccine
Journal
Medical microbiology and immunology
ISSN: 1432-1831
Titre abrégé: Med Microbiol Immunol
Pays: Germany
ID NLM: 0314524
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
09
09
2020
accepted:
08
01
2021
pubmed:
31
1
2021
medline:
20
8
2021
entrez:
30
1
2021
Statut:
ppublish
Résumé
Dengue virus (DENV) comprises four serotypes (DENV1-4) which cause 390 million global infections with 500,000 hospitalizations and 25,000 fatalities annually. Currently, the only FDA approved DENV vaccine is the chimeric live-attenuated vaccine, Dengvaxia®, which is based on the yellow fever virus (YFV) genome that carries the prM and E genes of the respective DENV 1, 2, 3, and 4 serotypes. However, it has lower efficacies against serotypes DENV1 (51%) and DENV2 (34%) when compared with DENV3 (75%) and DENV4 (77%). The absence of T cell epitopes from non-structural (NS) and capsid (C) proteins of the yellow fever vaccine strain might have prevented Dengvaxia® to elicit robust cellular immune responses, as CD8
Identifiants
pubmed: 33515283
doi: 10.1007/s00430-021-00700-x
pii: 10.1007/s00430-021-00700-x
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Antigens, Viral
0
Dengue Vaccines
0
Epitopes, B-Lymphocyte
0
Epitopes, T-Lymphocyte
0
Immunodominant Epitopes
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-11Subventions
Organisme : Sunway University (MY)
ID : Research Centre Grant 2020 (STR-RCTR-CVVR-01-2020)
Références
Ferreira-de-Lima VH, Lima-Camara TN (2018) Natural vertical transmission of dengue virus in Aedes aegypti and Aedes albopictus: a systematic review. Paras Vectors 11(1):77. https://doi.org/10.1186/s13071-018-2643-9
doi: 10.1186/s13071-018-2643-9
Martina BE, Koraka P, Osterhaus AD (2009) Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev 22(4):564–581. https://doi.org/10.1128/cmr.00035-09
doi: 10.1128/cmr.00035-09
pubmed: 19822889
pmcid: 2772360
Murray NE, Quam MB, Wilder-Smith A (2013) Epidemiology of dengue: past, present and future prospects. Clin Epidemiol 5:299–309. https://doi.org/10.2147/clep.s34440
doi: 10.2147/clep.s34440
pubmed: 23990732
pmcid: 3753061
Deng S-Q, Yang X, Wei Y, Chen J-T, Wang X-J, Peng H-J (2020) A review on dengue vaccine development. Vaccines (Basel) 8(1):63. https://doi.org/10.3390/vaccines8010063
doi: 10.3390/vaccines8010063
Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J (2010) Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 28(3):632–649. https://doi.org/10.1016/j.vaccine.2009.09.098
doi: 10.1016/j.vaccine.2009.09.098
pubmed: 19808029
Rosa BR, Cunha A, Medronho RA (2019) Efficacy, immunogenicity and safety of a recombinant tetravalent dengue vaccine (CYD-TDV) in children aged 2–17 years: systematic review and meta-analysis. BMJ Open 9(3):e019368. https://doi.org/10.1136/bmjopen-2017-019368
doi: 10.1136/bmjopen-2017-019368
pubmed: 30872537
pmcid: 6429993
Brewoo JN, Kinney RM, Powell TD, Arguello JJ, Silengo SJ, Partidos CD, Huang CYH, Stinchcomb DT, Osorio JE (2012) Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice. Vaccine 30(8):1513–1520. https://doi.org/10.1016/j.vaccine.2011.11.072
doi: 10.1016/j.vaccine.2011.11.072
pubmed: 22178727
Durbin AP, Kirkpatrick BD, Pierce KK, Elwood D, Larsson CJ, Lindow JC, Tibery C, Sabundayo BP, Shaffer D, Talaat KR, Hynes NA, Wanionek K, Carmolli MP, Luke CJ, Murphy BR, Subbarao K, Whitehead SS (2013) A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J Infect Dis 207(6):957–965. https://doi.org/10.1093/infdis/jis936
doi: 10.1093/infdis/jis936
pubmed: 23329850
pmcid: 3571448
Biswal S, Reynales H, Saez-Llorens X, Lopez P, Borja-Tabora C, Kosalaraksa P, Sirivichayakul C, Watanaveeradej V, Rivera L, Espinoza F, Fernando L, Dietze R, Luz K, Venâncio da Cunha R, Jimeno J, López-Medina E, Borkowski A, Brose M, Rauscher M, LeFevre I, Bizjajeva S, Bravo L, Wallace D (2019) Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. N Engl J Med 381(21):2009–2019. https://doi.org/10.1056/NEJMoa1903869
doi: 10.1056/NEJMoa1903869
pubmed: 31693803
Kirkpatrick BD, Durbin AP, Pierce KK, Carmolli MP, Tibery CM, Grier PL, Hynes N, Diehl SA, Elwood D, Jarvis AP, Sabundayo BP, Lyon CE, Larsson CJ, Jo M, Lovchik JM, Luke CJ, Walsh MC, Fraser EA, Subbarao K, Whitehead SS (2015) Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults. J Infect Dis 212(5):702–710. https://doi.org/10.1093/infdis/jiv082
doi: 10.1093/infdis/jiv082
pubmed: 25801652
pmcid: 4612392
Rivino L (2016) T cell immunity to dengue virus and implications for vaccine design. Exp Rev Vacc 15(4):443–453. https://doi.org/10.1586/14760584.2016.1116948
doi: 10.1586/14760584.2016.1116948
Sant AJ, McMichael A (2012) Revealing the role of CD4+ T cells in viral immunity. J Exp Med 209(8):1391–1395. https://doi.org/10.1084/jem.20121517
doi: 10.1084/jem.20121517
pubmed: 22851641
pmcid: 3420330
Tian Y, Grifoni A, Sette A, Weiskopf D (2019) Human T cell response to dengue virus infection. Front Immunol. 10:2125. https://doi.org/10.3389/fimmu.2019.02125
doi: 10.3389/fimmu.2019.02125
pubmed: 31552052
pmcid: 6737489
Kurane I, Meager A, Ennis FA (1989) Dengue virus-specific human T cell clones. Serotype crossreactive proliferation, interferon gamma production, and cytotoxic activity. J Exp Med 170(3):763–775. https://doi.org/10.1084/jem.170.3.763
doi: 10.1084/jem.170.3.763
pubmed: 2475573
Mathew A, Kurane I, Rothman AL, Zeng LL, Brinton MA, Ennis FA (1996) Dominant recognition by human CD8+ cytotoxic T lymphocytes of dengue virus nonstructural proteins NS3 and NS12a. J Clin Invest. 98(7):1684–1691. https://doi.org/10.1172/JCI118964
doi: 10.1172/JCI118964
pubmed: 8833919
pmcid: 507603
Gagnon SJ, Ennis FA, Rothman AL (1999) Bystander target cell lysis and cytokine production by dengue virus-specific human CD4+ cytotoxic T-lymphocyte clones. J Virol 73(5):3623
doi: 10.1128/JVI.73.5.3623-3629.1999
Hatch S, Endy TP, Thomas S, Mathew A, Potts J, Pazoles P, Libraty DH, Gibbons R, Rothman AL (2011) Intracellular cytokine production by dengue virus–specific T cells correlates with subclinical secondary infection. J Infect Dis 203(9):1282–1291. https://doi.org/10.1093/infdis/jir012
doi: 10.1093/infdis/jir012
pubmed: 21335561
pmcid: 3069729
de Matos AM, Carvalho KI, Rosa DS, Villas-Boas LS, da Silva WC, Rodrigues CL, Oliveira OM, Levi JE, Araújo ES, Pannuti CS, Luna EJ, Kallas EG (2015) CD8+ T lymphocyte expansion, proliferation and activation in dengue fever. PLoS Negl Trop Dis 9(2):e0003520. https://doi.org/10.1371/journal.pntd.0003520
doi: 10.1371/journal.pntd.0003520
pubmed: 25675375
pmcid: 4326415
Alves RPdS, Pereira LR, Fabris DLN, Salvador FS, Santos RA, Zanotto PMdA, Romano CM, Amorim JH, Ferreira LCdS (2016) Production of a recombinant dengue virus 2 NS5 protein and potential use as a vaccine antigen. Clin Vaccine Immunol 23(6):460. https://doi.org/10.1128/CVI.00081-16
doi: 10.1128/CVI.00081-16
pubmed: 27030586
pmcid: 4895003
Tian Y, Babor M, Lane J, Seumois G, Liang S, Goonawardhana NDS, De Silva AD, Phillips EJ, Mallal SA, da Silva AR, Grifoni A, Vijayanand P, Weiskopf D, Peters B, Sette A (2019) Dengue-specific CD8+ T cell subsets display specialized transcriptomic and TCR profiles. J Clin Invest 130(4):1727–1741. https://doi.org/10.1172/jci123726
doi: 10.1172/jci123726
Yauch LE, Zellweger RM, Kotturi MF, Qutubuddin A, Sidney J, Peters B, Prestwood TR, Sette A, Shresta S (2009) A protective role for dengue virus-specific CD8 T cells. J Immunol 182(8):4865. https://doi.org/10.4049/jimmunol.0801974
doi: 10.4049/jimmunol.0801974
pubmed: 19342665
pmcid: 2674070
Yauch LE, Prestwood TR, May MM, Morar MM, Zellweger RM, Peters B, Sette A, Shresta S (2010) CD4 T cells are not required for the induction of dengue virus-specific CD8 T cell or antibody responses but contribute to protection after vaccination. J Immunol 185(9):5405. https://doi.org/10.4049/jimmunol.1001709
doi: 10.4049/jimmunol.1001709
pubmed: 20870934
pmcid: 2962919
Zompi S, Santich BH, Beatty PR, Harris E (2012) Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells. J Immunol 188(1):404. https://doi.org/10.4049/jimmunol.1102124
doi: 10.4049/jimmunol.1102124
pubmed: 22131327
Pinto PBA, Assis ML, Vallochi AL, Pacheco AR, Lima LM, Quaresma KRL, Pereira BAS, Costa SM, Alves AMB (2019) T cell responses induced by DNA vaccines based on the DENV2 E and NS1 proteins in mice: importance in protection and immunodominant epitope Identification. Front Immunol 10:1522. https://doi.org/10.3389/fimmu.2019.01522
doi: 10.3389/fimmu.2019.01522
pubmed: 31333657
pmcid: 6617960
Weiskopf D, Yauch LE, Angelo MA, John DV, Greenbaum JA, Sidney J, Kolla RV, De Silva AD, de Silva AM, Grey H, Peters B, Shresta S, Sette A (2011) Insights into HLA-restricted T cell responses in a novel mouse model of dengue virus infection point toward new implications for vaccine design. J Immunol. 187(8):4268–4279. https://doi.org/10.4049/jimmunol.1101970
doi: 10.4049/jimmunol.1101970
pubmed: 21918184
pmcid: 3186824
Zellweger RM, Tang WW, Eddy WE, King K, Sanchez MC, Shresta S (2015) CD8 T cells can mediate short-term protection against heterotypic dengue virus reinfection in mice. J Virol 89(12):6494. https://doi.org/10.1128/JVI.00036-15
doi: 10.1128/JVI.00036-15
pubmed: 25855749
pmcid: 4474296
Li W, Joshi MD, Singhania S, Ramsey KH, Murthy AK (2014) Peptide vaccine: progress and challenges. Vaccines (Basel) 2(3):515–536. https://doi.org/10.3390/vaccines2030515
doi: 10.3390/vaccines2030515
Khan AM, Heiny AT, Lee KX, Srinivasan KN, Tan TW, August JT, Brusic V (2006) Large-scale analysis of antigenic diversity of T-cell epitopes in dengue virus. BMC Bioinform 7(Suppl 5):S4. https://doi.org/10.1186/1471-2105-7-s5-s4
doi: 10.1186/1471-2105-7-s5-s4
Jin X, Newman MJ, De-Rosa S, Cooper C, Thomas E, Keefer M, Fuchs J, Blattner W, Livingston BD, McKinney DM, Noonan E, Decamp A, Defawe OD, Wecker M (2009) A novel HIV T helper epitope-based vaccine elicits cytokine-secreting HIV-specific CD4+ T cells in a Phase I clinical trial in HIV-uninfected adults. Vaccine 27(50):7080–7086. https://doi.org/10.1016/j.vaccine.2009.09.060
doi: 10.1016/j.vaccine.2009.09.060
pubmed: 19786145
pmcid: 2784203
Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, Kast WM, Fascio G, Marty V, Weber J (2000) A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 6(9):3406–3416
pubmed: 10999722
Dong X-N, Wei K, Liu Z-Q, Chen Y-H (2002) Candidate peptide vaccine induced protection against classical swine fever virus. Vaccine 21(3):167–173. https://doi.org/10.1016/S0264-410X(02)00466-8
doi: 10.1016/S0264-410X(02)00466-8
pubmed: 12450690
Hiremath J, Kang K-i, Xia M, Elaish M, Binjawadagi B, Ouyang K, Dhakal S, Arcos J, Torrelles JB, Jiang X, Lee CW, Renukaradhya GJ (2016) Entrapment of H1N1 influenza virus derived conserved peptides in PLGA nanoparticles enhances T cell response and vaccine efficacy in pigs. PLoS ONE 11(4):e0151922–e0151922. https://doi.org/10.1371/journal.pone.0151922
doi: 10.1371/journal.pone.0151922
pubmed: 27093541
pmcid: 4836704
Purcell AW, McCluskey J, Rossjohn J (2007) More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discovery 6(5):404–414. https://doi.org/10.1038/nrd2224
doi: 10.1038/nrd2224
pubmed: 17473845
Robinson J, Halliwell JA, Hayhurst JD, Flicek P, Parham P, Marsh SG (2015) The IPD and IMGT/HLA database: allele variant databases. Nucleic Acids Res 43(Database issue):D423–431. doi: https://doi.org/10.1093/nar/gku1161
Roche PA, Furuta K (2015) The ins and outs of MHC class II-mediated antigen processing and presentation. Nat Rev Immunol 15(4):203–216. https://doi.org/10.1038/nri3818
doi: 10.1038/nri3818
pubmed: 25720354
pmcid: 6314495
Crotzer VL, Blum JS (2009) Autophagy and its role in MHC-mediated antigen presentation. J Immunol. 182(6):3335–3341. https://doi.org/10.4049/jimmunol.0803458
doi: 10.4049/jimmunol.0803458
pubmed: 19265109
pmcid: 2730830
Weiskopf D, Angelo MA, de Azeredo EL, Sidney J, Greenbaum JA, Fernando AN, Broadwater A, Kolla RV, De Silva AD, de Silva AM, Mattia KA, Doranz BJ, Grey HM, Shresta S, Peters B, Sette A (2013) Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci USA 110(22):E2046–E2053. https://doi.org/10.1073/pnas.1305227110
doi: 10.1073/pnas.1305227110
pubmed: 23580623
Ali M, Pandey RK, Khatoon N, Narula A, Mishra A, Prajapati VK (2017) Exploring dengue genome to construct a multi-epitope based subunit vaccine by utilizing immunoinformatics approach to battle against dengue infection. Sci Rep 7(1):9232. https://doi.org/10.1038/s41598-017-09199-w
doi: 10.1038/s41598-017-09199-w
pubmed: 28835708
pmcid: 5569093
Shi J, Sun J, Wu M, Hu N, Li J, Li Y, Wang H, Hu Y (2015) Inferring protective CD8+ T-cell epitopes for NS5 protein of four serotypes of dengue virus chinese isolates based on HLA-A, -B and -C allelic distribution: implications for epitope-based universal vaccine design. PLoS ONE 10(9):e0138729. https://doi.org/10.1371/journal.pone.0138729
doi: 10.1371/journal.pone.0138729
pubmed: 26381649
pmcid: 4575106
Chong LC, Khan AM (2019) Identification of highly conserved, serotype-specific dengue virus sequences: implications for vaccine design. BMC Genomics 20(Suppl 9):921–921. https://doi.org/10.1186/s12864-019-6311-z
doi: 10.1186/s12864-019-6311-z
pubmed: 31874646
pmcid: 6929274
Appanna R, Huat TL, See LL, Tan PL, Vadivelu J, Devi S (2007) Cross-reactive T-cell responses to the nonstructural regions of dengue viruses among dengue fever and dengue hemorrhagic fever patients in Malaysia. Clin Vacc Immunol 14(8):969–977. https://doi.org/10.1128/cvi.00069-07
doi: 10.1128/cvi.00069-07
Khan AM, Miotto O, Nascimento EJ, Srinivasan KN, Heiny AT, Zhang GL, Marques ET, Tan TW, Brusic V, Salmon J, August JT (2008) Conservation and variability of dengue virus proteins: implications for vaccine design. PLoS Negl Trop Dis 2(8):e272. https://doi.org/10.1371/journal.pntd.0000272
Bui HH, Sidney J, Peters B, Sathiamurthy M, Sinichi A, Purton KA, Mothé BR, Chisari FV, Watkins DI, Sette A (2005) Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics 57(5):304–314. https://doi.org/10.1007/s00251-005-0798-y
doi: 10.1007/s00251-005-0798-y
pubmed: 15868141
Bian H, Hammer J (2004) Discovery of promiscuous HLA-II-restricted T cell epitopes with TEPITOPE. Methods 34(4):468–475. https://doi.org/10.1016/j.ymeth.2004.06.002
doi: 10.1016/j.ymeth.2004.06.002
pubmed: 15542373
Nascimento EJM, Mailliard RB, Khan AM, Sidney J, Sette A, Guzman N, Paulaitis M, Melo ABd, Cordeiro MT, Gil LVG, Lemonnier F, Rinaldo C, August JT, Marques ETA Jr (2013) Identification of conserved and HLA promiscuous DENV3 T-cell epitopes. PLoS Negl Trop Dis 7(10):e2497. https://doi.org/10.1371/journal.pntd.0002497
doi: 10.1371/journal.pntd.0002497
pubmed: 24130917
pmcid: 3794980
Rivino L, Kumaran EA, Jovanovic V, Nadua K, Teo EW, Pang SW, Teo GH, Gan VC, Lye DC, Leo YS, Hanson BJ, Smith KG, Bertoletti A, Kemeny DM, MacAry PA (2013) Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection. J Virol 87(5):2693–2706. https://doi.org/10.1128/jvi.02675-12
doi: 10.1128/jvi.02675-12
pubmed: 23255803
pmcid: 3571409
Li S, Peng L, Zhao W, Zhong H, Zhang F, Yan Z, Cao H (2011) Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses. Vaccine 29(20):3695–3702. https://doi.org/10.1016/j.vaccine.2011.03.002
doi: 10.1016/j.vaccine.2011.03.002
pubmed: 21419774
Rocha RP, Livonesi MC, Fumagalli MJ, Rodrigues NF, da Costa LC, Dos Santos MC, de Oliveira Rocha ES, Kroon EG, Malaquias LC, Coelho LF (2014) Evaluation of tetravalent and conserved synthetic peptides vaccines derived from Dengue virus Envelope domain I and II. Virus Res 188:122–127. https://doi.org/10.1016/j.virusres.2014.04.009
doi: 10.1016/j.virusres.2014.04.009
pubmed: 24768848
Piazza P, Campbell D, Marques E, Hildebrand WH, Buchli R, Mailliard R, Rinaldo CR (2014) Dengue virus-infected human dendritic cells reveal hierarchies of naturally expressed novel NS3 CD8 T cell epitopes. Clin Exp Immunol 177(3):696–702. https://doi.org/10.1111/cei.12373
doi: 10.1111/cei.12373
pubmed: 24816171
pmcid: 4137854
Weiskopf D, Cerpas C, Angelo MA, Bangs DJ, Sidney J, Paul S, Peters B, Sanches FP, Silvera CGT, Costa PR, Kallas EG, Gresh L, de Silva AD, Balmaseda A, Harris E, Sette A (2015) Human CD8+ T-cell responses against the 4 dengue virus serotypes are associated with distinct patterns of protein targets. J Infect Dis 212(11):1743–1751. https://doi.org/10.1093/infdis/jiv289
doi: 10.1093/infdis/jiv289
pubmed: 25980035
pmcid: 4633759
Hertz T, Beatty PR, MacMillen Z, Killingbeck SS, Wang C, Harris E (2017) Antibody epitopes identified in critical regions of dengue virus nonstructural 1 protein in mouse vaccination and natural human infections. Journal of immunology (Baltimore, Md : 1950) 198 (10):4025–4035. doi: https://doi.org/10.4049/jimmunol.1700029
Hunt DF, Michel H, Dickinson TA, Shabanowitz J, Cox AL, Sakaguchi K, Appella E, Grey HM, Sette A (1992) Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science 256(5065):1817. https://doi.org/10.1126/science.1319610
doi: 10.1126/science.1319610
pubmed: 1319610
Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL (1994) Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264(5159):716. https://doi.org/10.1126/science.7513441
doi: 10.1126/science.7513441
pubmed: 7513441
Testa JS, Shetty V, Hafner J, Nickens Z, Kamal S, Sinnathamby G, Philip R (2012) MHC class I-presented T cell epitopes identified by immunoproteomics analysis are targets for a cross reactive influenza-specific T cell response. PLoS ONE 7(11):e48484. https://doi.org/10.1371/journal.pone.0048484
doi: 10.1371/journal.pone.0048484
pubmed: 23144892
pmcid: 3492461
Testa JS, Shetty V, Sinnathamby G, Nickens Z, Hafner J, Kamal S, Zhang X, Jett M, Philip R (2012) Conserved MHC class I-presented dengue virus epitopes identified by immunoproteomics analysis are targets for cross-serotype reactive T-cell response. J Infect Dis 205(4):647–655. https://doi.org/10.1093/infdis/jir814
doi: 10.1093/infdis/jir814
pubmed: 22246683
pmcid: 3297201
Bassani-Sternberg M, Barnea E, Beer I, Avivi I, Katz T, Admon A (2010) Soluble plasma HLA peptidome as a potential source for cancer biomarkers. Proc Natl Acad Sci 107(44):18769. https://doi.org/10.1073/pnas.1008501107
doi: 10.1073/pnas.1008501107
pubmed: 20974924
Ternette N, Yang H, Partridge T, Llano A, Cedeño S, Fischer R, Charles P, Dudek N, Mothe B, Crespo M, Fischer W, Korber B, Nielsen M, Borrow P, Purcell A, Brander C, Dorrell L, Kessler B, Hanke T (2015) Defining the HLA class I-associated viral antigen repertoire from HIV-1-infected human cells. Eur J Immunol. https://doi.org/10.1002/eji.201545890
doi: 10.1002/eji.201545890
pubmed: 26467324
pmcid: 4737398
Comber JD, Karabudak A, Huang X, Piazza PA, Marques ET, Philip R (2014) Dengue virus specific dual HLA binding T cell epitopes induce CD8+ T cell responses in seropositive individuals. Human Vacc Immunother 10(12):3531–3543. https://doi.org/10.4161/21645515.2014.980210
doi: 10.4161/21645515.2014.980210
Purcell AW, Ramarathinam SH, Ternette N (2019) Mass spectrometry–based identification of MHC-bound peptides for immunopeptidomics. Nat Protoc 14(6):1687–1707. https://doi.org/10.1038/s41596-019-0133-y
doi: 10.1038/s41596-019-0133-y
pubmed: 31092913
Shetty V, Nickens Z, Testa J, Hafner J, Sinnathamby G, Philip R (2012) Quantitative immunoproteomics analysis reveals novel MHC class I presented peptides in cisplatin-resistant ovarian cancer cells. J Proteom 75(11):3270–3290. https://doi.org/10.1016/j.jprot.2012.03.044
doi: 10.1016/j.jprot.2012.03.044